PharmacoEconomics & Outcomes News 804, p11 - 2 Jun 2018
Cost impact of expanding a home-
based HIV testing programme
Integrating screening for non-communicable diseases
(NCDs) into a home-based HIV testing and counselling
(HTC) programme "results in a modest increase in costs
with the potential to avert NCD death and disability,"
report researchers from South Africa and the US.
The researchers estimated the incremental costs of
integrating screening for NCDs (including diabetes
mellitus, hypertension, hypercholesterolaemia and
depression) as well as screening for NCD risk factors
(including obesity, tobacco and alcohol use) into a
home-based HTC programme. The study was
conducted in January 2015 in KwaZulu-Natal, South
Africa, and involved a cohort of 570 adults with a high
prevalence of HIV (33%).
The cost analysis showed that home-based integrated
HIV-NCD testing and counselling increased programme
costs by $US3.95 (42%) per person screened (from
$9.36 to $13.31). Personnel costs were the largest cost
component, representing 56% of the total costs,
followed by supplies (25%), transportation (8%), and
building and overhead (5%). The cost analysis also
showed that excluding lipid testing (at $1.71 per strip)
from NCD screening reduced marginal supply costs by
over 80% and overall incremental costs of integrated
HIV-NCD screening to 24%. "These cost data build on
the sparse economic evidence assessing the value of
innovative integrated models of care in low-middle
income settings," note the researchers.
Golovaty I, et al. Cost of integrating non-communicable disease screening into
home-based HIV testing and counseling in South Africa. JAIDS : 10 May 2018.
Available from: URL: http://doi.org/10.1097/QAI.0000000000001713
PharmacoEconomics & Outcomes News 2 Jun 2018 No. 8041173-5503/18/0804-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved